Why Quality Measures are Important

Quality measures are used to monitor patient care, connect clinical outcomes with healthcare processes, and meet third-party payer requirements. AAO-HNSF is committed to providing quality measures that meet our members’ requirements for public reporting to both CMS and private payers.

AAO-HNSF Qualified Clinical Data Registry (QCDR) measures are developed internally and only available to Reg-ent users. These are specialty-specific measures that have been approved by the Centers for Medicare & Medicaid Services for reporting in the Merit-based Incentive Payment System (MIPS).
- 18 specialty-specific AAO-HNSF developed QCDR measures

Quality Payment Program (QPP) measures for ENT are available publicly to any clinician reporting for MIPS and several were developed by AAO-HNSF.
- 44 public QPP measures applicable to otolaryngology-head and neck surgery

AAO-HNSF measures for validation or gap analysis are exclusively for Reg-ent users who express an interest in testing new measures for the specialty.
- Reg-ent also includes eight measures developed by AAO-HNSF for validation and gap analysis

To learn more about Reg-ent and the MIPS 2018 quality measures, visit www.reg-ent.org or email reg-ent@entnet.org. If you have any quality or measures specific questions, please contact us at measures@entnet.org.
## AAO-HNSF QCDR MEASURES

### OTITIS MEDIA WITH EFFUSION

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAO 8</td>
<td>Otitis Media with Effusion: Antihistamines or Decongestants - Avoidance of Inappropriate Use</td>
</tr>
<tr>
<td>AAO 11</td>
<td>Otitis Media with Effusion: Avoidance of Topical Intranasal Corticosteroids</td>
</tr>
<tr>
<td>AAO 20</td>
<td>Otitis Media with Effusion: Hearing Test</td>
</tr>
<tr>
<td>AAO 21</td>
<td>Audiometry for Chronic Otitis Media with Effusion in Children</td>
</tr>
<tr>
<td>AAO 26</td>
<td>Otitis Media with Effusion: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility</td>
</tr>
<tr>
<td>AAO 27</td>
<td>Otitis Media with Effusion: Resolution of Otitis Media with Effusion in Children*</td>
</tr>
<tr>
<td>AAO 28</td>
<td>Otitis Media with Effusion: Resolution of Otitis Media with Effusion in Adults*</td>
</tr>
</tbody>
</table>

### CERUMEN IMPACTION

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAO 15</td>
<td>Percentage of Patients with Cerumen Impaction and a Suggestive History of Non-Intact Tympanic Membrane Who Receive Just Manual Removal</td>
</tr>
<tr>
<td>AAO 18</td>
<td>Percentage of Visits with Patients with Hearing Aids Where Otoscopy is Routinely Performed</td>
</tr>
</tbody>
</table>

### ALLERGIC RHINITIS

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAO 22</td>
<td>Percentage of Patients with Allergic Rhinitis Who Do Not Receive Sinonasal Imaging for Allergic Rhinitis</td>
</tr>
<tr>
<td>AAO 23</td>
<td>Percentage of Patients with Allergic Rhinitis Who Are Offered Intranasal Corticosteroids or Oral Antihistamines</td>
</tr>
<tr>
<td>AAO 24</td>
<td>Percentage of Patients with Allergic Rhinitis Who Do Not Receive Leukotriene Inhibitors</td>
</tr>
<tr>
<td>AAO 25</td>
<td>Percentage of Patients with Allergic Rhinitis Who Do Not Receive IgG-based Immunoglobulin Testing</td>
</tr>
</tbody>
</table>

### AGE-RELATED HEARING LOSS

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAO 16</td>
<td>Audiometric Evaluation for Older Adults with Hearing Loss</td>
</tr>
<tr>
<td>AAO 17</td>
<td>Advanced Diagnostic Imaging of Bilateral Presbycusis or Symmetric Sensorineural Hearing Loss – Avoidance of Inappropriate Use</td>
</tr>
</tbody>
</table>

### BELL'S PALSY

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAO 13</td>
<td>Inappropriate Use of Magnetic Resonance Imaging or Computed Tomography Scan for Bell’s Palsy (Inverse Measure)</td>
</tr>
<tr>
<td>AAO 14</td>
<td>Inappropriate Use of Antiviral Monotherapy for Bell’s Palsy (Inverse Measure)</td>
</tr>
</tbody>
</table>

### TYMPANOSTOMY TUBES

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAO 12</td>
<td>Topical Ear Drop Monotherapy for Children with Acute Tympanostomy Tube Otorrhea</td>
</tr>
</tbody>
</table>

* Denotes an outcome measure  + Denotes high priority measure
### QPP MEASURES FOR ENT

#### ACUTE OTITIS EXTERNA
- **QPP 91** Acute Otitis Externa: Topical Therapy
- **QPP 93** Acute Otitis Externa: Systemic Antimicrobial Therapy

#### ADULT SINUSITIS
- **QPP 331** Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)
- **QPP 332** Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Acute Bacterial Sinusitis (Appropriate Use)
- **QPP 333** Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)
- **QPP 334** Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse)

#### ASTHMA
- **QPP 398** Optimal Asthma Control**+
- **QPP 444** Medication Management for People with Asthma+

#### FALLS
- **QPP 154** Falls: Risk Assessment+
- **QPP 155** Falls: Plan of Care+

#### OTITIS MEDIA WITH EFFUSION
- **QPP 464** Otitis Media with Effusion: Systemic Antimicrobials+

#### SLEEP APNEA
- **QPP 276** Sleep Apnea: Assessment of Sleep Symptoms
- **QPP 277** Sleep Apnea: Severity Assessment at Initial Diagnosis
- **QPP 278** Sleep Apnea: Positive Airway Pressure Therapy Prescribed
- **QPP 279** Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy

#### MEASURES FOR VALIDATION/GAP ANALYSIS ONLY

### AGE-RELATED HEARING LOSS
- Screening for Hearing Loss in Older Adults
- Shared Decision Making for Treatment Options for Bilateral Presbycusis or Symmetric Sensorineural Hearing Loss

### CERUMEN MANAGEMENT
- Percentage of Patients with Cerumen Impaction Who Receive Treatment with At Least One Appropriate Intervention

### HOARSENESS
- Postoperative Laryngeal Examination for Dysphonia

### TONSILLECTOMY
- Tonsillectomy: Primary Post-Tonsillectomy Hemorrhage in Children
- Tonsillectomy: Primary Post-Tonsillectomy Hemorrhage in Adults
- Tonsillectomy: Secondary Post-Tonsillectomy Hemorrhage in Children
- Tonsillectomy: Secondary Post-Tonsillectomy Hemorrhage in Adults

---

* Denotes an outcome measure  + Denotes high priority measure
### GENERAL QPP MEASURES

#### MEDICATION
- **QPP 46**  Medication Reconciliation Post-Discharge+
- **QPP 130**  Documentation of Current Medications in the Medical Record+
- **QPP 238**  Use of High-Risk Medications in the Elderly+

#### OPIOID THERAPY
- **QPP 408**  Opioid Therapy Follow-up Evaluation
- **QPP 412**  Documentation of Signed Opioid Treatment Agreement
- **QPP 414**  Evaluation or Interview for Risk of Opioid Misuse

#### PERIOPERATIVE CARE
- **QPP 21**  Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
- **QPP 23**  Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)+

#### PREVENTIVE CARE & SCREENING
- **QPP 110**  Preventive Care and Screening: Influenza Immunization
- **QPP 111**  Pneumococcal Vaccination Status for Older Adults
- **QPP 128**  Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
- **QPP 226**  Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
- **QPP 317**  Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
- **QPP 402**  Tobacco Use and Help with Quitting Among Adolescents
- **QPP 431**  Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling

#### RESPIRATORY DISEASES
- **QPP 65**  Appropriate Treatment for Children with Upper Respiratory Infection (URI)
- **QPP 66**  Appropriate Testing for Children with Pharyngitis
- **QPP 116**  Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis

#### SURGERY
- **QPP 355**  Unplanned Reoperation within the 30-Day Postoperative Period*+
- **QPP 356**  Unplanned Hospital Readmission within 30 Days of Principal Procedure*+
- **QPP 357**  Surgical Site Infection (SSI)*+
- **QPP 358**  Patient-Centered Surgical Risk Assessment and Communication+

#### OTHER
- **QPP 47**  Care Plan+
- **QPP 131**  Pain Assessment and Follow-Up+
- **QPP 261**  Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness+
- **QPP 265**  Biopsy Follow-Up+
- **QPP 374**  Closing the Referral Loop: Receipt of Specialist Report+
- **QPP 404**  Anesthesiology Smoking Abstinence+
- **QPP 435**  Quality of Life Assessment For Patients With Primary Headache Disorders*+

* Denotes an outcome measure  + Denotes high priority measure

To learn more about Reg-ent and the MIPS 2018 quality measures, visit [www.reg-ent.org](http://www.reg-ent.org) or email [reg-ent@entnet.org](mailto:reg-ent@entnet.org).

If you have any quality or measures specific questions please contact us at [measures@entnet.org](mailto:measures@entnet.org).